SB Capital Management Inc Invests $11.54 Million in Capricor Therapeutics, Inc. $CAPR

SB Capital Management Inc purchased a new position in Capricor Therapeutics, Inc. (NASDAQ:CAPR) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 400,001 shares of the biotechnology company’s stock, valued at approximately $11,544,000. Capricor Therapeutics accounts for approximately 4.2% of SB Capital Management Inc’s investment portfolio, making the stock its 5th biggest position.

A number of other large investors also recently modified their holdings of CAPR. Suvretta Capital Management LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter valued at about $51,533,000. Tang Capital Management LLC bought a new position in Capricor Therapeutics in the 4th quarter valued at about $49,062,000. RA Capital Management L.P. bought a new position in Capricor Therapeutics in the 4th quarter valued at about $43,516,000. Darwin Global Management Ltd. acquired a new position in Capricor Therapeutics during the 4th quarter valued at about $23,168,000. Finally, Vanguard Group Inc. raised its position in shares of Capricor Therapeutics by 16.1% during the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock worth $73,936,000 after buying an additional 355,161 shares in the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on CAPR shares. Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Roth Mkm reiterated a “buy” rating and set a $38.00 price objective on shares of Capricor Therapeutics in a research note on Friday, May 15th. Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Finally, B. Riley Financial upped their target price on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $48.36.

Capricor Therapeutics Stock Up 1.5%

NASDAQ:CAPR opened at $28.38 on Friday. The business’s 50-day moving average price is $30.50 and its 200 day moving average price is $28.06. Capricor Therapeutics, Inc. has a 52-week low of $4.30 and a 52-week high of $40.37. The firm has a market cap of $1.64 billion, a P/E ratio of -12.23 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). Sell-side analysts expect that Capricor Therapeutics, Inc. will post -0.75 EPS for the current year.

Insider Buying and Selling

In related news, CFO Anthony Bergmann sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $260,669.10. This trade represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karimah Es Sabar sold 7,529 shares of Capricor Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total transaction of $240,928.00. Following the completion of the transaction, the director owned 7,529 shares in the company, valued at approximately $240,928. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 172,529 shares of company stock worth $5,302,440 over the last quarter. Insiders own 9.20% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.